FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081133477> ?p ?o ?g. }

• W3081133477 abstract "9622 Background: Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor. It is a widely used angiogenesis inhibitor in the treatment of colorectal cancer (CRC) and other solid tumors. Gastrointestinal (GI) perforation is a potentially fatal adverse event associated with bevacizumab, but the risk unclear. This study was conducted to determine the risk of developing GI perforation among CRC and non-CRC patients receiving bevacizumab. Methods: Databases from PUBMED and the Web Science from January 1966 until July 2008 and abstracts presented at the American Society of Clinical Oncology conferences from January 2000 to through July 2008 were searched to identify relevant studies. Eligible studies included prospective phase III clinical trials in which standard anti-neoplastic therapy was administered with and without the use of bevacizumab with available data for GI perforation. Summary incidence rate, relative risk (RR), and 95% confidence interval (CI) were calculated using fixed or random effect models based upon the heterogeneity of the included studies. Results: A total of 12084 patients with various solid tumors from 14 phase III trials were included for analysis. Among patients receiving bevacizumab, the incidence of GI perforation was 0.8% (95% CI: 0.6–1.1%), and RR was 2.0 (95% CI: 1.1–3.8, p = 0.028) in compared with controls. The risk of GI perforation was significantly increased in patients receiving bevacizumab at 5 mg/kg/week (RR 2.6, 95% CI: 1.0–6.6, p=0.04), but not at 2.5 mg/kg/week (RR=1.5, 95%CI: 0.7–3.3, p=0.3). Among 2151 patients with CRC, the incidence of GI perforation was 0.8% (95% CI: 0.5–1.6%); while for 2.999 patients with non-CRC malignancies, the incidence of GI perforation was 0.7% (95% CI: 0.5–1.1%); The relative risk of GI perforation varied with tumor type, with significantly increased risk observed in patients with CRC (RR = 3.1, 95% CI: 1.2–8.2, p<0.023), but not non-CRC (RR=1.5, 95% CI: 0.67–3.4, p=0.3). Conclusions: There is a significant difference in the risk of developing GI perforation in CRC and non-CRC patients receiving bevacizumab with a higher relative risk in patients with CRC. Further investigation into the etiology of this difference is recommended. No significant financial relationships to disclose." @default.
• W3081133477 created "2020-09-01" @default.
• W3081133477 creator A5020103730 @default.
• W3081133477 creator A5026865145 @default.
• W3081133477 creator A5057910703 @default.
• W3081133477 date "2009-05-20" @default.
• W3081133477 modified "2023-09-24" @default.
• W3081133477 title "Risk of bevacizumab-associated gastrointestinal perforation in patients with colorectal cancer and noncolorectal cancer" @default.
• W3081133477 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.9622" @default.
• W3081133477 hasPublicationYear "2009" @default.
• W3081133477 type Work @default.
• W3081133477 sameAs 3081133477 @default.
• W3081133477 citedByCount "0" @default.
• W3081133477 crossrefType "journal-article" @default.
• W3081133477 hasAuthorship W3081133477A5020103730 @default.
• W3081133477 hasAuthorship W3081133477A5026865145 @default.
• W3081133477 hasAuthorship W3081133477A5057910703 @default.
• W3081133477 hasConcept C121608353 @default.
• W3081133477 hasConcept C126322002 @default.
• W3081133477 hasConcept C143998085 @default.
• W3081133477 hasConcept C191897082 @default.
• W3081133477 hasConcept C192562407 @default.
• W3081133477 hasConcept C2776694085 @default.
• W3081133477 hasConcept C2777802072 @default.
• W3081133477 hasConcept C2778456384 @default.
• W3081133477 hasConcept C2778527123 @default.
• W3081133477 hasConcept C2780199535 @default.
• W3081133477 hasConcept C2780356529 @default.
• W3081133477 hasConcept C3018436397 @default.
• W3081133477 hasConcept C526805850 @default.
• W3081133477 hasConcept C542804219 @default.
• W3081133477 hasConcept C71924100 @default.
• W3081133477 hasConcept C81182388 @default.
• W3081133477 hasConceptScore W3081133477C121608353 @default.
• W3081133477 hasConceptScore W3081133477C126322002 @default.
• W3081133477 hasConceptScore W3081133477C143998085 @default.
• W3081133477 hasConceptScore W3081133477C191897082 @default.
• W3081133477 hasConceptScore W3081133477C192562407 @default.
• W3081133477 hasConceptScore W3081133477C2776694085 @default.
• W3081133477 hasConceptScore W3081133477C2777802072 @default.
• W3081133477 hasConceptScore W3081133477C2778456384 @default.
• W3081133477 hasConceptScore W3081133477C2778527123 @default.
• W3081133477 hasConceptScore W3081133477C2780199535 @default.
• W3081133477 hasConceptScore W3081133477C2780356529 @default.
• W3081133477 hasConceptScore W3081133477C3018436397 @default.
• W3081133477 hasConceptScore W3081133477C526805850 @default.
• W3081133477 hasConceptScore W3081133477C542804219 @default.
• W3081133477 hasConceptScore W3081133477C71924100 @default.
• W3081133477 hasConceptScore W3081133477C81182388 @default.
• W3081133477 hasLocation W30811334771 @default.
• W3081133477 hasOpenAccess W3081133477 @default.
• W3081133477 hasPrimaryLocation W30811334771 @default.
• W3081133477 hasRelatedWork W2021596330 @default.
• W3081133477 hasRelatedWork W2040803852 @default.
• W3081133477 hasRelatedWork W2043304606 @default.
• W3081133477 hasRelatedWork W2095374934 @default.
• W3081133477 hasRelatedWork W2096893939 @default.
• W3081133477 hasRelatedWork W2099279915 @default.
• W3081133477 hasRelatedWork W2111275107 @default.
• W3081133477 hasRelatedWork W2137611924 @default.
• W3081133477 hasRelatedWork W2315082777 @default.
• W3081133477 hasRelatedWork W2326145287 @default.
• W3081133477 hasRelatedWork W2347206335 @default.
• W3081133477 hasRelatedWork W2347697088 @default.
• W3081133477 hasRelatedWork W2366546138 @default.
• W3081133477 hasRelatedWork W2520860251 @default.
• W3081133477 hasRelatedWork W2608341410 @default.
• W3081133477 hasRelatedWork W2738195070 @default.
• W3081133477 hasRelatedWork W2932562167 @default.
• W3081133477 hasRelatedWork W3031693100 @default.
• W3081133477 hasRelatedWork W2948696183 @default.
• W3081133477 hasRelatedWork W3065159083 @default.
• W3081133477 isParatext "false" @default.
• W3081133477 isRetracted "false" @default.
• W3081133477 magId "3081133477" @default.
• W3081133477 workType "article" @default.